Barinthus Biotherapeutics plc.
DelistedCIK 1828185fmd_1FD0EGRPXDQ7EMWJ733ZRG48S1Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Jun 30, 2026, 26 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Total revenues | 5 | 0 | 45 | 1 | 15 | 0 |
| Research and development | 14 | 20 | 42 | 45 | 42 | 26 |
| Total operating expenses | 25 | 45 | 49 | 85 | 84 | 71 |
| Operating income | (20) | (45) | (4) | (84) | (68) | (71) |
| Interest expense | 4 | 3 | 0 | 0 | 0 | 0 |
| Interest and investment income | 0 | 0 | 3 | 3 | 3 | 2 |
| Other non-operating income (expense) | 2 | (6) | 5 | 7 | 7 | 4 |
| Income before taxes | – | (51) | 1 | (77) | (61) | (67) |
| Income tax expense | 0 | (0) | (4) | (3) | (0) | (0) |
| Net income from continuing operations | – | (51) | 5 | (73) | (61) | (66) |
| Net income | (18) | (51) | 5 | (73) | (61) | (66) |